ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population

B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar

University of Illinois at Chicago, Chicago, IL

Meeting: 2019 American Transplant Congress

Abstract number: A244

Keywords: Co-stimulation, Immunosuppression, Kidney, Nephrotoxicity

Session Information

Date: Saturday, June 1, 2019

Session Name: Poster Session A: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

Related Abstracts
  • Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
  • Clinical Outcomes and Risk Factors for Delayed or Slow Graft Function in an Adult, Urban Renal Transplant Population

*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge exists regarding the clinical impact of this strategy on high-risk, obese, and racially diverse patients. The purpose of this study was to compare renal, cardiovascular, and metabolic health outcomes pre- and post-belatacept conversion in a high-risk, urban RTx population.

*Methods: This was a retrospective cohort study of high-risk patients who underwent RTx from 1/1/2012-12/31/2017 and were converted to belatacept. High-risk RTx was defined as: African American race, panel reactive antibody > 10%, re-transplant, or positive flow-crossmatch. The primary outcome was to compare estimated glomerular filtration rate (eGFR) at time of belatacept conversion to 6 months post-conversion. Secondary outcomes included incidence of biopsy-proven acute rejection (BPAR) post-conversion, and comparisons of cardiovascular, metabolic, and infectious outcomes. Obesity and conversion timing (early conversion < 90 days post-RTx) were assessed to determine impact on percent change in eGFR (%eGFR) pre- versus 6 months post-conversion. Data were compared with McNeamer's test, paired t-test, and Wilcoxon signed ranks test.

*Results: 21 RTx recipients were analyzed. A majority of patients were male (66.7%), African American (76.2%) undergoing belatacept conversion with a starting dose of 10mg/kg (85.7%) at a median of 53 days post-RTx. CNI nephrotoxicity (47.6%) was the major conversion indication. Table 1 details demographic information. Estimated GFR improved significantly (pre-conversion 35.0 mL/min/1.732 vs. 6 months post-conversion 54.5 mL/min/1.732, p=0.001). Four patients (19.5%) experienced a BPAR at a median of 123 (IQR 40 – 263.5) days post-conversion. Despite this finding, eGFR was higher after belatacept conversion at all time points (Figure 1). Obese patients experienced a larger numeric improvement in %eGFR compared to non-obese patients (68.4% vs 20.7%, p = 0.143). Late conversion did not impact %eGFR (p=0.379). No differences in cardiovascular, metabolic, and infectious outcomes post-conversion were observed (Table 2).

*Conclusions: Belatacept conversion can be accomplished in a high-risk population. BPAR is of concern, but allograft function improvement is evident as early as 1 month post-conversion. Larger studies examining risks for post-conversion rejection and allograft response are essential to identifying the best method in this complex population.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Valdepenas B, Benken J, Benedetti E, Hajjiri Z, Lichvar A. Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-implications-of-belatacept-conversion-in-a-high-risk-urban-renal-transplant-population/. Accessed March 8, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.